Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pfizer-BioNTech COVID-19 vaccine with pembrolizumab and chemotherapy in stage IV NSCLC
NCT07597070Phase 2Recruiting
- Sponsor
- University of Florida
- Start
- Nov 2026
- Primary completion
- Mar 2035
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tozinameran in non-small cell lung cancer (NSCLC) (3 arms), sponsored by University of Florida. Primary endpoint: Incidence of immune-related adverse events requiring hospitalization at 60 days. Started Nov 2026; status: recruiting.
02
Drugs
tozinameran
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07597070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07597070.